Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.36 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29162430 | 1.00 | OPRM1 (0.47) | OPRM1OPRD1DGAT1OPRK1PARP10 | |
| SCHEMBL23357298 | 0.85 | OPRD1 (0.58) | OPRM1OPRD1OPRK1 | |
| SCHEMBL23357299 | 0.85 | OPRD1 (0.58) | OPRM1OPRD1OPRK1 | |
| SCHEMBL23357241 | 0.83 | OPRD1 (0.48) | OPRM1OPRD1OPRK1 | |
| SCHEMBL23357137 | 0.83 | OPRD1 (0.48) | OPRM1OPRD1OPRK1 | |
| SCHEMBL23357243 | 0.83 | OPRD1 (0.48) | OPRM1OPRD1OPRK1 | |
| SCHEMBL23357139 | 0.83 | OPRD1 (0.48) | OPRM1OPRD1OPRK1 | |
| SCHEMBL25151743 | 0.81 | TDP1 (0.35) | OPRM1OPRD1OPRK1 | |
| SCHEMBL23357098 | 0.80 | OPRD1 (0.62) | OPRM1OPRD1 | |
| SCHEMBL23357095 | 0.80 | OPRK1 (0.43) | OPRD1OPRK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4320105-A1 | OPIOID RECEPTOR MODULATORS | Epiodyne, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-117425644-A | Opioid receptor modulators | 埃皮欧黛公司 | 2024-01-19 | — | — | CN | disclosed |
| US-11634396-B2 | Opioid receptor modulators | EPIODYNE, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| WO-2022216750-A1 | OPIOID RECEPTOR MODULATORS | EPIODYNE, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634396-B2 | Opioid receptor modulators | OPRM1, OPRK1, OPRL1 | OPRM1 1/4885OPRD1 4/4885DGAT1 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.